Tscan Therapeutics Inc is trading 5.3% up at $0.96 in pre-market action, tracking a broad risk-on tone in U.S. equity futures as markets react to geopolitical developments.
- The move appears driven by a tentative U.S.–Iran peace agreement, which has boosted global markets while easing energy and inflation concerns.
- Biotech and other rate-sensitive growth sectors are broadly benefiting from the shift in sentiment, helping the stock bounce from recent losses.
- There is currently a lack of fresh company-specific headlines, suggesting the price action is primarily macro-driven.